MELBOURNE, Australia, Dec. 2 /PRNewswire/ -- Meditron Pty., Ltd. today announced that the first ever HIFU (High Intensity Focused Ultrasound) surgery with tele-remote link to an academic institution was performed for the treatment of prostate cancer at Cabrini Medical Centre. Cabrini Medical Centre in Melbourne is a leading institution for prostate cancer treatment in Australia.
The Sonablate(R) 500 uses advanced HIFU energy which is sharply focused and destroys targeted prostate tissue without affecting the intervening tissue. The advanced Sonablate(R) technology has been used to treat over 2,500 men for prostate cancer around the world.
The treating urologist, Dr. Peter Royce said, “We are very excited to be using HIFU technology as a curative, noninvasive treatment for localized prostate cancer. The patient went home the next day without pain or complications.” Dr. Royce is a leading urologist at the Cabrini Medical Centre and was trained in Japan on the most advanced HIFU techniques. He said, “This treatment is excellent for patients that have early stage prostate cancer, wish to maintain a high quality of life post-treatment and want to avoid radical surgery and radiation therapy.”
Meditron Pty., Ltd. is the exclusive distributor for the advanced Sonablate(R) 500 for treatment of localized and recurrent prostate cancer, and is the first company to introduce this technology to Australia. The advanced HIFU Sonablate(R) 500 system, designed for the minimally invasive treatment of prostate cancer, was introduced to Australia after 6 years of clinical use in Tokyo, Japan and other centres around the world.
Michael Fehrmann, Managing Director of Meditron Pty., Ltd. said, “We have had strong response from both patients and doctors for this technology since we introduced it to Australia in August. This advanced technology has the potential to revolutionize the way men’s prostate health is delivered in Australia.” Meditron is also a leading provider of minimally invasive, therapeutic urology products, including Dornier lithotriptors and surgical lasers.
The Sonablate(R) 500 is an advanced HIFU technology system developed by Focus Surgery, Inc., (Indianapolis, IN) for the treatment of prostate diseases.
More information available at: http://www.hifu.net.au
Meditron Pty., Ltd.; Cabrini Medical Centre
CONTACT: Michael Fehrmann, Managing Director of Meditron, Pty., Ltd., Ph:+61 (03) 9879-6200, Email: info@meditron.com.au ; or David Quigley,President of THS International, Inc., +1-317-541-1580, Email:info@thsinternational.com
